ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors

Zhang, Rujia; Zhao, Haoran; Wang, Peng; Guo, Zuoming; Liu, Chunxun; Qu, Zhaowei*哈尔滨医科大学
BMC CANCER2023-12-1DOI: 10.1186/s12885-023-11678-5
9阅读
引用收藏
分享

摘要

Objective The predictive biomarkers of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) still need to be further explored. This study aims to establish a new immune prognosis biomarker to predict the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.Methods The subjects of this study were 151 HCC patients receiving ICIs at Harbin Medical University Cancer Hospital from January 2018 to December 2021. This study collected a wide range of blood parameters from patients before treatment and used Cox's regression analysis to identify independent prognostic factors in blood parameters, as well as their beta coefficient. The hepatocellular carcinoma immune prognosis score (HCIPS) was established through Lasso regression analysis and COX multivariate analysis. The cut-off value of HCIPS was calculated from the receiver operating characteristic (ROC) curve. Finally, the prognostic value of HCIPS was validated through survival analysis, stratified analyses, and nomograms.Results HCIPS was composed of albumin (ALB) and thrombin time (TT), with a cut-off value of 0.64. There were 56 patients with HCIPS < 0.64 and 95 patients with HCIPS >= 0.64, patients with low HCIPS were significantly related to shorter progression-free survival (PFS) (13.10 months vs. 1.63 months, P < 0.001) and overall survival (OS) (14.83 months vs. 25.43 months, P < 0.001). HCIPS has also been found to be an independent prognostic factor in this study. In addition, the stratified analysis found a significant correlation between low HCIPS and shorter OS in patients with tumor size >= 5 cm (P of interaction = 0.032). The C-index and 95% CI of the nomograms for PFS and OS were 0.730 (0.680-0.779) and 0.758 (0.711-0.804), respectively.Conclusions As a new score established based on HCC patients receiving ICIs, HCIPS was significantly correlated with clinical outcomes in patients with ICIs and might serve as a new biomarker to predict HCC patients who cloud benefit from ICIs.

学科与关键词

关键词
Prognosis scoreHepatocellular carcinomaImmune checkpoint inhibitorsClinical outcomesNon-invasive biomarkers
相关
加载中…
  • Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors
    Liu, Chunxun; Zhao, Haoran; Zhang, Rujia; Guo, Zuoming; Wang, Peng; Qu, Zhaowei*Oncology Letters, 2023, 26(4): 437.
  • Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors
    Hong, Chang; Dong, Han-Zhi; Li, Rui-Ning; Zhu, Hong-Bo; Li, Qi-Mei; Cui, Hao; Hu, Cheng-Yi; Huang, Chao-Yi; Peng, Jie; Liu, Li*; Zou, Xue-Jing*; Xiao, Lu-Shan*DIGESTIVE DISEASES, 2023, 41(3): 422-430.被引 3
  • Early C-reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma
    Qin, Qiuying; Kou, Xiaoxuan; Zheng, Yuanyuan; Zhou, Fei; Zhang, Xiaoyong*; Liu, Hongyan*Journal of Hepatocellular Carcinoma, 2023, 10: 2009-2019.
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-12-01
卷期
第 23 卷, 第 1 期
页码
1181
DOI
10.1186/s12885-023-11678-5
语言
ENGLISH
成果收录
SCIE
资助标注
Beijing Medical and Health Foundation

作者

  • Z

    Zhang, Rujia (第一作者)

    2 · harbin med univ

  • Z

    Zhao, Haoran

    harbin med univ

查看全部 6 位作者收起作者
  • W

    Wang, Peng

    harbin med univ

  • G

    Guo, Zuoming

    harbin med univ

  • L

    Liu, Chunxun

    harbin med univ

  • Q

    Qu, Zhaowei (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417